close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by XBiotech Inc.

XBiotech Pauses Rheumatology program
From XBiotech Inc.
Via GlobeNewswire
Tickers XBIT
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
From XBiotech Inc.
Via GlobeNewswire
Tickers XBIT
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
From XBiotech Inc.
Via GlobeNewswire
Tickers XBIT
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
From XBiotech Inc.
Via GlobeNewswire
Tickers XBIT
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
From XBiotech Inc.
Via GlobeNewswire
Tickers XBIT
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
From XBiotech Inc.
Via GlobeNewswire
Tickers XBIT
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
From XBiotech Inc.
Via GlobeNewswire
Tickers XBIT
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
From XBiotech Inc.
Via GlobeNewswire
Tickers XBIT
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
From XBiotech Inc.
Via GlobeNewswire
Tickers XBIT
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
From XBiotech Inc.
Via GlobeNewswire
Tickers XBIT
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
From XBiotech Inc.
Via GlobeNewswire
Tickers XBIT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today